The expanding use of newborn screening is revealing a puzzling metabolic condition where biochemical abnormalities don't necessarily predict health problems. Short-chain acyl-CoA dehydrogenase deficiency affects how the body processes certain amino acids, yet many affected individuals show no symptoms despite clear laboratory abnormalities. This disconnect challenges traditional assumptions about metabolic disorders and their clinical management.
Three Slovakian patients with ACADSB gene variants demonstrated elevated C5-acylcarnitine levels and specific urinary metabolites including 2-methylbutyrylglycine and 2-ethyl-3-hydroxypropionate. Two patients carried confirmed pathogenic genetic variants, while biomarker levels showed notable fluctuation over time within the same individuals. The C5/C8 acylcarnitine ratio proved inconsistent as a diagnostic marker, remaining normal in one patient despite persistently elevated C5 levels.
This variability reflects a broader challenge in precision medicine: distinguishing between biochemical variants that require intervention versus those representing benign genetic diversity. Unlike classical metabolic disorders where enzyme deficiencies cause severe symptoms, ACADSB deficiency appears to exist on a spectrum from completely asymptomatic to potentially problematic. The inconsistent metabolite patterns suggest environmental factors, dietary influences, or compensatory metabolic pathways may modulate disease expression. For healthcare providers and parents, these findings highlight the complexity of interpreting newborn screening results and underscore the need for individualized monitoring approaches rather than blanket treatment protocols for detected metabolic variants.